Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).
In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Qinhan Chen
- Telefonnummer: +86 021-50831718
- E-Mail: Insilico-Clinicaltrial@insilico.ai
Studienorte
-
-
Anhui
-
Hefei, Anhui, China
- Noch keine Rekrutierung
- Anhui Provincial Hospital
-
Hefei, Anhui, China
- Noch keine Rekrutierung
- Anhui Chest Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Rekrutierung
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, China
- Rekrutierung
- Beijing Friendship hospital, Capital Medical University
-
Beijing, Beijing Municipality, China
- Noch keine Rekrutierung
- Beijing Chaoyang Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, China
- Noch keine Rekrutierung
- Fuzhou University Affiliated Provincial Hospital
-
Xiamen, Fujian, China
- Rekrutierung
- The Second Affiliated Hospital of Xiamen Medical College
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Rekrutierung
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Guangdong, China
- Noch keine Rekrutierung
- Nanfang Hospital, Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, China
- Noch keine Rekrutierung
- The First Affiliated Hospital of Guangxi Medical University
-
-
Hainan
-
Haikou, Hainan, China
- Rekrutierung
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China
- Noch keine Rekrutierung
- The Second Hospital of Hebei Medical University
-
Shijiazhuang, Hebei, China
- Noch keine Rekrutierung
- Hebei Medical University Third Hospital
-
-
Henan
-
Anyang, Henan, China
- Rekrutierung
- The People's Hospital of Anyang City
-
Nanyang, Henan, China
- Rekrutierung
- Nanyang First People's Hospital
-
Zhengzhou, Henan, China
- Noch keine Rekrutierung
- Henan Provincial People's Hospital
-
Zhengzhou, Henan, China
- Noch keine Rekrutierung
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, China
- Noch keine Rekrutierung
- Renmin Hospital of Wuhan University
-
Wuhan, Hubei, China
- Noch keine Rekrutierung
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Yichang, Hubei, China
- Noch keine Rekrutierung
- Yichang Central People's Hospital
-
-
Hunan
-
Changsha, Hunan, China
- Noch keine Rekrutierung
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, China
- Noch keine Rekrutierung
- The Xiangya Hospital of Central South University
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, China
- Noch keine Rekrutierung
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Rekrutierung
- Nanjing Drum Tower Hospital
-
Xuzhou, Jiangsu, China
- Noch keine Rekrutierung
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Noch keine Rekrutierung
- Jiangxi Provincial People' Hospital
-
-
Jilin
-
Changchun, Jilin, China
- Noch keine Rekrutierung
- The Second Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, China
- Noch keine Rekrutierung
- Shengjing Hospital of China Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- Rekrutierung
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xi'an, Shaanxi, China
- Rekrutierung
- The First Affiliated Hospital of Xi'an Medical College
-
-
Shandong
-
Jinan, Shandong, China
- Noch keine Rekrutierung
- Qilu Hospital of Shandong University
-
Jinan, Shandong, China
- Noch keine Rekrutierung
- Introduction of the First Affiliated Hospital of Shandong First Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Rekrutierung
- Shanghai Pulmonary Hospital Affiliated to Tongji University
-
-
Shanxi
-
Taiyuan, Shanxi, China
- Noch keine Rekrutierung
- Shanxi Bethune Hospital
-
Yuncheng, Shanxi, China
- Noch keine Rekrutierung
- Yuncheng Central Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China
- Noch keine Rekrutierung
- West China Hospital, Sichuan University
-
Chengdu, Sichuan, China
- Noch keine Rekrutierung
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China
- Noch keine Rekrutierung
- Tianjin Medical University General Hospital
-
Tianjin, Tianjin Municipality, China
- Noch keine Rekrutierung
- Tianjin Chest Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, China
- Noch keine Rekrutierung
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, China
- Noch keine Rekrutierung
- The First People Hospital of Yunnan Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Noch keine Rekrutierung
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, China
- Rekrutierung
- Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
-
Jiaxing, Zhejiang, China
- Noch keine Rekrutierung
- The First Hospital of Jiaxing
-
Ningbo, Zhejiang, China
- Noch keine Rekrutierung
- Ningbo Medical Center Lihuili Hospital
-
Ningbo, Zhejiang, China
- Noch keine Rekrutierung
- The First Affiliated Hospital of Ningbo University
-
Wenzhou, Zhejiang, China
- Noch keine Rekrutierung
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
- Patients aged ≥40 years at time of signing the ICF.
- Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
- UIP or probable UIP with fibrosis extent >10% at HRCT.
Meet all the following criteria during the screening period:
- FVC ≥45% predicted of normal
- FEV1/FVC ≥0.7
- DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
Background antifibrotic therapies are allowed, patients may be either:
- on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
- not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
- Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
- Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.
Exclusion criteria:
- Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
- Previous participation in a clinical study with rentosertib (active or placebo).
- Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
- Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
- Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
- Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
- Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
- Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
- Patients with Gilbert's disease
- Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
- Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
- Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
- Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
- Patient with a history of lung volume reduction surgery or lung transplant.
- Current smoker and/or cotinine (smoking) test positive.
- History of drug abuse, drug use, or alcohol abuse within the past 3 months.
- Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
- Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
- Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
- Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study
- Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
- Medications associated with substantial risk for prolongation of corrected QT interval.
- Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
- Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
- Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
- Any condition that would interfere with the interpretation of study assessments or impair study participation.
- Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
|
Dosage form: Tablets; Frequency of administration: Orally QD.
Other Names: Rentosertib
|
|
Placebo-Komparator: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
|
Darreichungsform: Tablette; Häufigkeit der Verabreichung: Oral QD.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
Zeitfenster: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
time to first occurrence of any disease progression
Zeitfenster: up to 52 weeks
|
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
|
up to 52 weeks
|
|
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
Zeitfenster: week 52
|
week 52
|
|
|
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
Zeitfenster: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
Zeitfenster: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
Zeitfenster: Weeks 0, 52
|
Weeks 0, 52
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
Zeitfenster: up to 56 weeks
|
up to 56 weeks
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
Zeitfenster: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
Zeitfenster: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
Zeitfenster: weeks 0, 12 ,26, and 52
|
weeks 0, 12 ,26, and 52
|
|
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
Zeitfenster: weeks 0, 52
|
weeks 0, 52
|
|
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
Zeitfenster: weeks 0, 52
|
weeks 0, 52
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- INS018-055-301
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .